Amarin Corp Plc (AMRN)

[sts66]

A drug that combats CV19 with anti-inflammatory activity should not have different results for various strains unless a variant causes different medical problems, something not in evidence. Vaccine efficacy is a different animal to treatment efficacy. I hope we see V helps at least a little bit, but I'm not counting on it - may not be enough severe cases to get stat sig data - and I don't believe V will have any efficacy in preventing infection, MOA doesn't match.

And yeah, scripts are depressing, worse than last year and no growth in the combined market. Even worse, check out this plot by Captbeer - the refill rate dropped by -23% AFTER the R-IT results came out - how the hell does that make sense?